August 25, 2016 About
About
http://transitionrx.com/page,4/About Adam Robles 1440
November 12, 2013 Prep Education
Prep Education
http://transitionrx.com/page,199/Prep_Education Jason Riddle 1440
October 30, 2013 Products & Services
Products & Services
http://transitionrx.com/page,194/Products___Services Jason Riddle 1440
October 30, 2013 AssureCare Communication
AssureCare Communication
http://transitionrx.com/page,196/AssureCare_Communication Jason Riddle 1440
October 30, 2013 Contact Us
Contact Us
http://transitionrx.com/page,193/Contact_Us Jason Riddle 1440
October 30, 2013 GoodPatient
GoodPatient
http://transitionrx.com/page,200/GoodPatient Jason Riddle 1440
October 24, 2013 PT Journey Card
PT Journey Card
http://transitionrx.com/page,198/PT_Journey_Card Jason Riddle 1440
October 24, 2013 Pharmacy Services
Pharmacy Services
http://transitionrx.com/page,197/Pharmacy_Services Jason Riddle 1440
September 3, 2013 Home
Home
http://transitionrx.com/page,1/Home Jason Riddle 1440
August 16, 2013 Partners
Partners
http://transitionrx.com/page,188/Partners Jason Riddle 1440
June 6, 2013 News
News
http://transitionrx.com/page,191/News Adam Robles 1440
May 21, 2013 Case Studies
Case Studies
http://transitionrx.com/page,192/Case_Studies Jason Riddle 1440
December 10, 2012 Terms and Conditions
Terms and Conditions
http://transitionrx.com/page,187/Terms_and_Conditions Jason Riddle 1440
June 16, 2016 EY announces Transition Patient Services President and CEO Christopher Di Lascia named EY Entrepreneur Of The Year® 2016 Medical Services Award winner in Greater Philadelphia
TREVOSE, PA – June 10th, 2016 – EY today announced that Dr. Christopher Di Lascia, Pharm.D of Transition Patient Services, a pharmacy distribution and patient engagement services company, received the Greater Philadelphia EY Entrepreneur Of The Year® 2016 Award for Medical Services. The award recognizes outstanding entrepreneurs who demonstrate excellence, innovation, and personal commitment to their businesses and communities. “I am proud to share this award with the TPS team and with our customers who make this achievement possible. We all are bound together by our commitment to improving health outcomes for the patients we serve. We remain committed to our vision of improving each patient’s healthcare journey through personalized patient support and evidence-based solutions that reduce barriers to medication access and help our clients reach their clinical, financial, and organizational performance goals.” Since 1986, EY has honored entrepreneurs whose ingenuity, spirit of innovation and discipline have propelled their companies’ success, invigorated their industries, and benefited their communities. Now in its 30th year, the program has honored the inspirational leadership of such entrepreneurs as Howard Schultz of Starbucks Coffee Company, Robert Unanue of Goya Foods, and Mindy Grossman of HSN. Recent US national winners include Reid Hoffman and Jeff Weiner of LinkedIn; Hamdi Ulukaya, founder of Chobani; and 2015 winners Andreas Bechtolsheim and Jayshree Ullal of Arista Networks. As a Greater Phliadelphia award winner, <Name> is now eligible for consideration for the Entrepreneur Of The Year 2016 national program. Award winners in several national categories, as well as the Entrepreneur Of The Year National Overall Award winner, will be announced at the Entrepreneur Of The Year National Awards gala in Palm Springs, California, on November 19, 2016. The awards are the culminating event of the Strategic Growth ForumTM, the nation’s most prestigious gathering of high-growth, market- leading companies. The US Entrepreneur Of The Year Overall Award winner then moves on to compete for the World Entrepreneur Of The Year Award in Monaco, June 2017. Sponsors Founded and produced by EY, the Entrepreneur Of The Year Awards are sponsored nationally by SAP America, Merrill Corporation and the Ewing Marion Kauffman Foundation. In Greater Philadelphia, sponsors also include PNC Bank, Pine Hill Group, LLP, SolomonEdwards Group, Ballard Spahr LLP, Morgan Lewis, Pepper Hamilton LLP, Simkiss & Block and Philadelphia Business Journal. About EY Entrepreneur Of The Year® EY Entrepreneur Of The Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries. About Transition Patient Services At TPS we understand that successful outcomes start with the patient, and rely heavily on proper use of medication. Through our commitment to improved medication management, increased patient engagement, and "patient first" customer service, TPS fulfills our mission of simplifying medication access, reducing prescription abandonment, and enhancing patient adherence through confirmed medication acquisition. For over twelve years, our customers have been assured medication gets in the hands of well-supported patients, helping keep each patient on a positive journey toward better health. About EY EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities. 
http://transitionrx.com/news/action,view/id,9/EY-announces-Transition-Patient-Services-President-and-CEO-Christopher-Di-Lascia-named-EY-Entrepreneur-Of-The-Year®-2016-Medical-Services-Award-winner-in-Greater-Philadelphia Adam Robles 1440
September 17, 2015 Mission Pharmacal relaunches Lithostat
SAN ANTONIO — Mission Pharmacal announced Friday that it would be relaunching its Lithostat (acetohydroxamic acid) kidney stones treatment. The reintroduction comes as part of a partnership with a French company that supplies the drug’s active ingredients and a distribution arrangement with specialty supplier Transition Patient Services. “The partnership with TPS enables Mission to provide a patient-friendly service and to make Lithostat available with a consistent and convenient delivery method,” Mission Pharmacal’s executive director of urological and specialty sales Steve Gornto said. “Now everyone knows how and where to get the product and related information. Mission can serve Lithostat patients and do so in an efficient way.”  The company said that the arrangement with TPS would allow its team to reach out to urologists and nephrologists with literature on the drug and provide more information about the kidney stone treatment and how to fulfill orders for Lithostat. “With the relaunch, Mission is doing everything we can to stand behind the patient and physician to help make sure the people who rely on Lithostat get the therapy they need,” Gornto said.  *Source: Drug Store News : Mission Pharmacal relaunches Lithostat
http://transitionrx.com/news/action,view/id,8/Mission-Pharmacal-relaunches-Lithostat Jason Riddle 1440
July 29, 2014 Akrimax Pharmaceuticals Initiates CONTROL Patient Registry for Tirosint®
Contacts:                               J. Gregory Ford, Akrimax (Business Development)908-372-1232gford@akrimax.com                                                                Annie Starr, 6 Degrees (Media)(973) 415-8838astarr@6degreespr.com   FOR IMMEDIATE RELEASE Akrimax Pharmaceuticals Initiates CONTROL Patient Registry for Tirosint® (levothyroxine sodium) Capsules  Post-marketing study to assess efficacy and tolerability of Tirosint in hypothyroid patients inadequately controlled with traditional T4 therapy  Cranford, NJ (July 29, 2014) – Akrimax Pharmaceuticals, LLC, a privately held, innovative specialty pharmaceutical company, today announced the initiation of its patient registry study in hypothyroidism called CONTROL:  CONversion to Tirosint Results in better management of hypOthyroidism and improved quality of Life. The post-marketing study will assess the efficacy and tolerability of Tirosint® (levothyroxine sodium) capsules in hypothyroidism patients who are inadequately controlled with, or intolerant of, traditional levothyroxine (T4) tablets. Tirosint, the first and only T4 available in a liquid gel cap, is approved by the U.S. Food and Drug Administration for the treatment of hypothyroidism. CONTROL is an open-label observational study in which patients who have not previously achieved target thyroid-stimulating hormone (TSH) levels with traditional T4 tablets will be switched to Tirosint at a dose deemed appropriate for the individual. TSH levels will be measured every 4-6 weeks and dose titrations will be made, as needed. In addition, patients will complete a quality of life survey called ThyTSQ before starting Tirosint and at the end of the treatment period. The study is expected to enroll patients at sites throughout the U.S. starting immediately. Charles Pollack, MD, lead study investigator and Chief Medical Officer of Transition Patient Services, said, “Patients with hypothyroidism, particularly those who also have gastrointestinal disorders like celiac disease and H. pylori infection, may have trouble tolerating or absorbing traditional T4 tablets. This hinders them from achieving normal TSH levels. CONTROL will evaluate Tirosint therapy in these patients in order to provide documentation of Tirosint’s effectiveness and tolerability, as well as offer insights about hypothyroid patients’ quality of life before and after Tirosint treatment. We anticipate having results by early 2016 and look forward to publishing our findings to help better inform hypothyroidism treatment decisions.” CONTROL has been approved by the Western Institutional Review Board.   About Hypothyroidism Hypothyroidism is an endocrine disorder with numerous causes resulting in a deficiency in thyroid hormone. More than 27 million adult Americans have been diagnosed with hypothyroidism,1 and up to 13 million Americans have undiagnosed hypothyroidism.2 About 2% of the U.S. population has pronounced hypothyroidism, and as much as 10% has subclinical (mild) hypothyroidism. The condition is most common in women over 40 years of age and in the elderly of both sexes.3 Common symptoms of hypothyroidism may include fatigue, forgetfulness, depression, constipation, muscle cramps, weight gain, dry skin and hair loss.4 Laboratory tests (TSH, FT3 and FT4) are the most common way hypothyroidism is detected. Treatment with levothyroxine sodium oral tablets is the standard of care in hypothyroidism.   About Tirosint® (levothyroxine sodium) capsules Tirosint (levothyroxine sodium) is the first and only levothyroxine therapy in a liquid gel cap. Tirosint gel caps are pure. Tirosint gel caps contain only T4, water, glycerin, and gelatin.  Tirosint is available in 10 dosage strengths, including an exclusive 13 microgram dose. Tirosint is administered as a single daily dose, preferably one-half to one-hour before breakfast. Tirosint should be taken at least 4 hours apart from drugs that are known to interfere with its absorption. Tirosint capsules cannot be cut or crushed. Due to the long half-life of levothyroxine, the peak therapeutic effect at a given dose of levothyroxine sodium may not be attained for 4-6 weeks. Tirosint capsules are housed in blister packs to protect it from light and moisture. Blister packs are clearly marked for daily dosing. Tirosint should be protected from light and moisture and stored at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F).   IMPORTANT SAFETY INFORMATION  WARNINGS Thyroid hormones, including TIROSINT, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce  serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.  In patients with nontoxic diffuse goiter or nodular thyroid disease, particularly the elderly or those with underlying cardiovascular disease, levothyroxine sodium therapy is contraindicated if the serum TSH level is already suppressed due to the risk of precipitating overt thyrotoxicosis. If the serum TSH level is not suppressed, TIROSINT should be used with caution in conjunction with careful monitoring of thyroid function for evidence of hyperthyroidism and clinical monitoring for potential associated adverse cardiovascular signs and symptoms of hyperthyroidism.   CONTRAINDICATIONS Levothyroxine is contraindicated in patients with untreated subclinical (suppressed serum TSH level with normal T3 and T4 levels) or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction. Levothyroxine is contraindicated in patients with uncorrected adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by increasing the metabolic clearance of glucocorticoids. TIROSINT is contraindicated in patients with hypersensitivity to any of the inactive ingredients in TIROSINT capsules. TIROSINT is also contraindicated for anyone who may be unable to swallow a capsule (e.g., infants, small children).   PRECAUTIONS Effects on bone mineral density – In women, long-term levothyroxine sodium therapy has been associated with increased bone resorption, thereby decreasing bone mineral density, especially in postmenopausal women on greater than replacement doses or in women who are receiving suppressive doses of levothyroxine sodium. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase and suppressed serum parathyroid hormone levels. Therefore, it is recommended that patients receiving levothyroxine sodium be given the minimum dose necessary to achieve the desired clinical and biochemical response. Patients with underlying cardiovascular disease – Exercise caution when administering levothyroxine to patients with cardiovascular disorders and to the elderly in whom there is an increased risk of occult cardiac disease. In these patients, levothyroxine therapy should be initiated at lower doses than those recommended in younger individuals or in patients without cardiac disease and it should be noted that unlike levothyroxine sodium tablets, TIROSINT capsules cannot be cut in half. If cardiac symptoms develop or worsen, the levothyroxine dose should be reduced or withheld for one week and then cautiously restarted at a lower dose. Overtreatment with levothyroxine sodium may have adverse cardiovascular effects such as an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias. Patients with coronary artery disease who are receiving levothyroxine therapy should be monitored closely during surgical procedures, since the possibility of precipitating cardiac arrhythmias may be greater in those treated with levothyroxine. Concomitant administration of levothyroxine and sympathomimetic agents to patients with coronary artery disease may precipitate coronary insufficiency.   ADVERSE REACTIONS Adverse reactions associated with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdosage such as fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating, and other adverse reactions. This is not an exhaustive list. Please refer to TIROSINT’s full Prescribing Information for a more comprehensive list of adverse reactions associated with hyperthyroidism. For Tirosint full Prescribing Information, go to www.Tirosint.com.  About Akrimax Pharmaceuticals Akrimax Pharmaceuticals, LLC is a privately held, innovative specialty pharmaceutical company that acquires, develops and markets advanced ethical prescription medications. Akrimax’s marketed products include:  SuprenzaTM, PrimlevTM, Tirosint®, NitroMist®, Inderal LA®, and InnoPran XL®. In order to bring the best treatments to patients, Akrimax is continuously evaluating opportunities to partner with other organizations that strive to improve patient care.  For more information, visit www.akrimax.com.   References 1 Spinger, G. 2011. Published online at: www.personalhealthconnections.com/2011/thyroiddisease-why-this-epidemic 2 Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med. 2000;160:526-534. 3 McDermott MT. In the clinic: hypothyroidism. Ann Intern Med. 2009;151(11): ITC-6–ITC-1. 4 “FAQ: Hypothyroidism” American Thyroid Association, 2012.  Published online at: http://www.thyroid.org/faq-hypothyroidism/   
http://transitionrx.com/news/action,view/id,7/Akrimax-Pharmaceuticals-Initiates-CONTROL-Patient-Registry-for-Tirosint® Jason Riddle 1440
June 3, 2014 FDA Approves SYNERA® (lidocaine and tetracaine) Topical Patch for Home Use
SOUDERTON, PA, June 3, 2014 – Galen US Incorporated today announced that the U.S. Food and Drug Administration (FDA) recently approved a labeling change that allows SYNERA®1 (lidocaine and tetracaine) topical patch to be used at home. SYNERA® is a technological advance that can help prevent needle stick pain associated with superficial IVs and superficial dermatological procedures; it combines two commonly used numbing medications (lidocaine and tetracaine) with warming technology in a simple-to-use peel-and-stick patch. 1 “The SYNERA® patch has been a game changer for our family,” said Kelley Carthey, a Registered Nurse and mother of three. “Before we used SYNERA®, my son, who has type 1 diabetes, often feared the needle and pain that accompanied insertion of his continuous glucose monitoring sensor. But now, we use SYNERA® before I need to insert the sensor, and he doesn’t even wince.” As part of SYNERA®’s availability for home use, Galen US has partnered with Transition Patient Services (TPS) to offer direct-to-patient home delivery of the product through the SYNERA® Now Access Program (SNAP). A health care professional can fax or e-prescribe a prescription for SYNERA® to TPS. The patient will then be contacted by a TPS pharmacist for processing and delivery information. After the call, TPS will mail SYNERA® directly to the patient. “Pain and discomfort associated with needle stick is real for some patients, especially children. That’s why we’re proud to offer SYNERA® as a local dermal anesthetic to help improve patients’ experiences with superficial IVs and superficial dermatological procedures,” said Andrew Shales, General Manager, Galen US Incorporated. “With our expanded offering of SYNERA® for home use and direct-to-patient home delivery, we hope to provide patients with convenience and reassurance during their treatments.” KEY FACTS   IV access is rated as one of the most common sources of significant pain and anxiety in pediatric hospitals.2   SYNERA® is faster acting than EMLA®, a local anesthetic comprised of lidocaine and prilocaine in a topical cream, at helping to prevent needle stick pain; SYNERA® works within 20 to 30 minutes of application vs. at least 1 hour of application of EMLA®.1,3,4   SYNERA® is approved for use in adults and children as young as three years old. 1 For more information on SYNERA® and mail order delivery, visit www.synera.com. Media Contact: Sarah Cooper 215.928.2184 sarah.cooper@toniclc.com About Synera® (lidocaine and tetracaine) Topical Patch SYNERA® is a prescription patch that contains a mixture of lidocaine, tetracaine, and a gentle warming technology that helps prevent pain associated with superficial venous access and superficial dermatological procedures. 1 When applied to intact skin, it helps prevent needle stick pain within 20 to 30 minutes. 3 SYNERA® is approved for use in adults and children as young as three years old. 1 SYNERA® is contraindicated in patients with a known history of sensitivity to lidocaine, tetracaine, local anesthetics of the amide or ester type, hypersensitivity to para-aminobenzoic acid (PABA), or sensitivity to any other component of the product. In clinical studies, some skin reactions occurred at the application site, including redness, blanching, and swelling. These reactions were generally mild and went away without the need for any treatment. Allergic reactions such as hives, difficulty breathing, skin redness or swelling, and shock can occur. In a randomized, double-blind, placebo-controlled study, 59% of children aged 3 to 17 years reported no pain upon the needle stick compared with only 20% among children who were given a patch with no numbing medications (n=61, P5 About Galen Established in 1968, Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland), with products in therapy areas including gastroenterology, urology, female health and pain management. As a subsidiary of Galen Limited, Galen US also has a small presence in oncology and plans to continue expanding its portfolio with selected specialty products on an international basis. By combining innovation in product development with competitive pricing, Galen aims to work in partnership with healthcare professionals and patients to create real, long-term value. Important Safety Information for SYNERA® (lidocaine and tetracaine) Topical Patch SYNERA® topical patch is indicated for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures. SYNERA® is contraindicated in patients with a known history of sensitivity to lidocaine, tetracaine, local anesthetics of the amide or ester type, or any other component of the product and in patients with para-aminobenzoic acid (PABA) hypersensitivity. Keeping a patch on longer than recommended or applying multiple patches simultaneously or sequentially could result in systemic absorption sufficient to result in serious adverse effects that are typical of drugs in this class. Used SYNERA® patches contain a large amount of lidocaine and tetracaine (at least 90% of the initial amount). Chewing or ingesting a new or used SYNERA® patch may result in serious adverse effects. Store and dispose of SYNERA® out of the reach of children and pets. SYNERA® should be used with caution in patients who may be more sensitive to the systemic effects of lidocaine and tetracaine, particularly the acutely ill, the debilitated, and those with compromised hepatic function. Patients with severe hepatic disease or pseudocholinesterase deficiency are at greater risk of developing toxic plasma concentrations. SYNERA® should be used with caution in patients with a history of methemoglobinemia (refer to full Prescribing Information). Do not use on mucous membranes or on areas with a compromised skin barrier. Application to broken or inflamed skin may result in toxic blood concentrations of lidocaine and tetracaine. Allergic or anaphylactoid reactions (urticaria, angioedema, bronchospasm, and shock) to the active or inactive components of SYNERA® can occur and should be managed by conventional means. Avoid contact of SYNERA® with the eyes due to potential irritation or abrasion. If contact occurs, immediately wash out the eye with water or saline, and protect it until sensation returns. Simultaneous or sequential application of more than two SYNERA® patches to children is not recommended as it has not been adequately studied. Safety and effectiveness of SYNERA® have been established in patients 3 years and older. Lidocaine has been shown to inhibit viral and bacterial growth. The effect of SYNERA® on intradermal injections of live vaccines has not been determined. The heating component contains iron powder, and the patch must be removed before magnetic resonance imaging. SYNERA® may lead to diminished or blocked sensation in the treated skin; therefore, patients should avoid inadvertent trauma (rubbing, scratching, or exposure to heat or cold) before complete sensation returns. SYNERA® should be used with caution in patients receiving class I antiarrhythmics and/or other local anesthetics, because the systemic toxic effects may be additive and potentially synergistic with lidocaine and tetracaine. In clinical studies, the most common local reactions were erythema (71%) blanching (12%), and edema (12%); these reactions were generally mild, resolving spontaneously soon after patch removal. Do not cut or remove the top cover of the patch as this could result in thermal injury. Please see full SYNERA® Prescribing Information. 
http://transitionrx.com/news/action,view/id,6/FDA-Approves-SYNERA®-(lidocaine-and-tetracaine)-Topical-Patch-for-Home-Use Jason Riddle 1440
April 11, 2013 Transition Patient Services Announces Joint Development Agreement with with iMPak Health
Transition Patient Services Announces Joint Development Agreement with with iMPak Health  Neptune, New Jersey, August 5th, 2013 —iMPak Health, a subsidiary of Meridian Health, today announced a joint development agreement with Transition Patient Services (TPS) for comprehensive, integrated care management solutions. The initial areas of joint development are focused on Congestive Heart Failure, Chronic Obstructive Pulmonary Disease and overall Medication Compliance.  iMPak Health’s devices and TPS’s interactive platform will create offerings that bring patient generated data into an actionable clinical workflow.  “We are excited to partner with iMPak Health in developing innovative, patient focused solutions” says Chris Di Lascia, Pharm. D. President of TPS.  “Both our companies share a strategic vision of enhancing patient care through the integration of low cost, seamless technology into the care process that enables patients and professional caregivers to actively manage health and assure better outcomes across a range of chronic medical conditions more cost-effectively.” TPS will integrate its AssureCare communication management platform with iMPak Health devices to deliver a proactive patient management capability that includes algorithm driven patient education, reminders and support. In addition, iMPak and TPS are working with a nationally-known data integrator so that the process of care, the data captured via TPS platform, and the use of ImPak Health integrated devices, will be assembled and reported to the patient, family and medical professional via an EHR or PHR or both, as needed. “Patients and caregivers are the most under utilized resource in helping to manage chronic conditions.  Our joint efforts will enable patient engagement across multiple types of conditions and technology platforms”, says Sandra Elliott, Executive Director, iMPak Health. The first program to utilize the integrated TPS-iMPak Health technology and the iMPak Connect Portal will be the newly launched medication management solution, Kraken, an iMPak Health medication monitoring and management solution that provides a unique, user friendly alternative allowing patients and physicians to organize, track and outline prescription schedules freely and accurately. With Kraken, iMPak Health aims to simplify medication management through the combination of medication sorting with proactive, “as needed” patient reminders, and patient compliance and symptom tracking, necessary to facilitate success in today’s “performance based” payment initiatives. About iMPak Health Founded by Meridian Health, a leading not-for-profit health care organization in New Jersey, iMPak Health brings together the latest in wireless technology and the front-line know-how of today’s health care environment to provide consumers and patients with effective and intuitive tools to better manage their health. iMPak Health’s mission is to become a leader in developing, easy-to-use devices to screen, diagnose, and monitor health conditions. To learn more about iMPak Health, visit www.iMPakHealth.com About Transition Patient Services TPS designs and delivers technology-enhanced solutions that facilitate medication access, streamline health care communication, empower patients, caregivers, and healthcare providers.  Since its founding eight years ago, TPS has provided services to patients, physicians, and hospitals in a wide range of therapeutic areas and a diverse spectrum of patient populations, helping improve outcomes and drive improvement in healthcare ROI. To learn more about Transition Patient Services, visit www.transitionrx.com
http://transitionrx.com/news/action,view/id,3/Transition-Patient-Services-Announces-Joint-Development-Agreement-with-with-iMPak-Health Jason Riddle 1440
January 4, 2013 Transition Patient Services to Support Underwood-Memorial Hospital Implementation of Care Transition Services
TREVOSE, PA – Transition Patient Services (TPS) has been selected by Underwood-Memorial Hospital, Woodbury, NJ, to help support the design and implementation of the hospital’s transition of care system. Underwood Memorial Hospital has been awarded a two-year, $300,000 grant from the Robert Wood Johnson Foundation (RWJF) through its New Jersey Health Initiatives (NJHI). The grant supports the establishment of a Community Hospital Based Integrated Delivery System, Centered around Patient Transition of Care. The hospital projects that 1,500 patients annually, aged 65 years and over, will receive services supported by the grant. “We are excited to be a part of the transition of care process at Underwood,” says Christopher Di Lascia, president & CEO of TPS. “Underwood’s was one of nine projects to receive this funding through NJHI, reassuring us that we are launching an innovative strategy to bring improved health care to the residents of communities served by this award winning hospital.” “This project is unique and exciting,” notes Barbara Roehl, MD, MBA, geriatrician and the chief clinical integration officer for Underwood who will direct the grant. “The intention of this is to ensure that our patients receive, and then take their prescribed medicines properly, and receive the appropriate care services once they are discharged from Underwood to the next level of care. Also important to a successful transition is the patient’s involvement in disease and medication self management, recognition of health issues or “red flags” that need attention, and timely outpatient follow-up. We believe TPS will play a critical role in our achieving these goals. “The experts have told hospitals that we have to remove the word ‘discharge’ from our vocabulary. In the future, Underwood, as a health care provider, will never lose responsibility for that patient’s well-being once they are no longer in a hospital bed—under the hospital roof. The patient transitions to home, or skilled nursing facility, or a long-term care nursing facility—levels of care that Underwood is now partnering with in this effort.” Underwood’s partners in this Transitions of Care start first, and foremost, with the patient and the patient’s caregivers. Then, depending on the patient’s needs, TPS will help connect the patient with an expanded network to include a local pharmacy, coverage for prescription and co-pay assistance for the uninsured, rehabilitation and nursing homes, home care, and the Gloucester County Division of Senior Services. The Robert Wood Johnson Foundation focuses on the pressing health and health care issues facing our country. As the nation’s largest philanthropy devoted exclusively to improving the health and health care of all Americans, the Foundation works with a diverse group of organizations and individuals to identify solutions and achieve comprehensive, meaningful, and timely change. For more than 35 years, the Foundation has brought experience, commitment, and a rigorous, balanced approach to the problems that affect the health and health care of those it serves. When it comes to helping Americans lead healthier lives and get the care they need—the Foundation expects to make a difference in your lifetime. For more information, visit www.rwif.org. Underwood is a 305-licensed bed, acute care, non-profit hospital with a medical staff of over 400 physicians, and is Gloucester County’s largest employer.
http://transitionrx.com/news/action,view/id,4/Transition-Patient-Services-to-Support--Underwood-Memorial-Hospital-Implementation--of-Care-Transition-Services Jason Riddle 1440
July 19, 2012 HIV/AIDS patient assistance foundation HarborPath teams up with TPS for the design, development, and ongoing operation of a innovative medication access system for underserved patients.
TPS Creates a Single Portal for HarborPath to Provide Uninsured Individuals Improved Access HIV/AIDS Medications   Washington, DC – July 19, 2012 – HarborPath, a new, non-profit organization, has been established to create a program that offers a single place for application and medication fulfillment for uninsured individuals living with HIV/AIDS who otherwise qualify for manufacturer-sponsored patient assistance programs. As part of the project team, Transition Patient Services (TPS), designed and delivered a “one stop shop” portal to provide  streamlined, online process to qualify individuals and deliver the donated medications through a mail-order pharmacy.   To create the portal, TPS worked closely with the HarborPath, National Alliance of State and Territorial AIDS Directors (NASTAD) and the Clinton Health Access Initiative (CHAI), which provided the seed funding for the organization. On World AIDS Day 2011, President Clinton, building on his longstanding commitment to combating HIV/AIDS domestically, noted the need to fight HIV/AIDS in the United States.    “HarborPath’s new program addresses a critical need, and answers this call for a renewed emphasis on the domestic HIV epidemic,” said President Clinton. “I am proud that my Foundation is partnering with NASTAD and other pharmaceutical manufacturers to make sure Americans living with HIV have access to the life-saving medications they need. This is an important step forward in our fight against the disease.”   HarborPath will pilot the program in states with high need including Alabama, Texas and Virginia.   Need for a Streamlined Application Process The Centers for Disease Control and Prevention (CDC) and other sources estimate that the number of people living with HIV/AIDS in the United States is 1.2 million.[i] According to the Institute of Medicine, 325,000 of those 1.2 million people are uninsured and are not supported by federal programs like Medicaid or Medicare.[ii] The economic downturn has caused such programs, including the AIDS Drug Assistance Programs (ADAP) to lower the income eligibility levels required for participation, resulting in an unknown but potentially significant number of individuals who are no longer able to receive their medications through these systems.   Murray Penner, Deputy Executive Director at NASTAD, said, “Under the current PAP process, an individual or their case manager has to apply separately to each company’s program for these medications, which can be complex and time-consuming. Thankfully, individuals are living longer with HIV/AIDS due to combination antiretroviral treatments. Missing doses or failing to fill prescriptions because of complications sometimes associated with these processes may result in serious health consequences, or even death, in addition to increased transmission of the virus. HarborPath is designed to address this urgent need in the United States.”   A New Solution to Access HIV/AIDS Medications “Pharmaceutical company-sponsored prescription assistance programs serve as an invaluable safety net for low-income, uninsured individuals,” said Ken Trogdon, Jr., President of HarborPath. “Our program will simplify the process for the thousands of individuals living with HIV/AIDS who fall out of the system. HarborPath has evolved from discussions and requests from the community and the industry for a collaborative, seamless solution for the uninsured.” The goal of HarborPath is to get all HIV/AIDS medications into the program and serve uninsured individuals with: An easy-to-use website with a ‘single’ portal to determine eligibility for the program and fulfills prescriptions for participating company’s HIV/AIDS medications. Automatic notifications for both the individual and the case manager of qualification for the program. A pharmacy that ships a 3-month supply of all participating medications in one package within 2 business days of final approval and confirms delivery of the medications. Renewal reminders to individuals and case managers to improve medication adherence, and A fully automated portal that case managers can access at any time for up-to-the-minute status of an individual’s application or shipment. If needed, live support is also available through a toll-free call center.   “I am pleased to be working with President Clinton to make the process easier for individuals living with HIV/AIDS and their caregivers to access life-saving medications,” said Congresswoman Barbara Lee of California, Co-Chair of the Congressional HIV/AIDS Caucus. “I’m hopeful the progress we have made since coming together on World AIDS Day will bring relief as waiting lists for antiretroviral therapies continue to grow at alarming rates, particularly in the South. HarborPath fills an overwhelming need and I encourage all stakeholders to offer their assistance to help people obtain the essential medications they need.”    About HarborPath HarborPath is a new 501 (c) 3 non-profit organization dedicated to assisting low-income, uninsured people living with HIV/AIDS gain access to their entire regimen of brand-name prescription medications at no cost through a single portal. For more information, visit www.harborpath.org.   About the Clinton Health Access Initiative The Clinton Health Access Initiative (CHAI) began in 2002 as the Clinton HIV/AIDS Initiative to address the HIV/AIDS crisis in the developing world and strengthen health systems there. Taking the lead from governments and working with partners, CHAI has improved markets for medicines and diagnostics, lowered the costs of treatment, and expanded access to life-saving technologies – creating a sustainable model that can be owned and maintained by governments. CHAI has since expanded this model to increase access to high-quality treatment for malaria, accelerate the rollout of new vaccines, and lower infant mortality. Today, more than 4 million people are benefiting from medicines purchased under CHAI agreements.  About NASTAD Founded in 1992, NASTAD is a nonprofit national association of state and territorial health department HIV/AIDS program directors who have programmatic responsibility for administering HIV/AIDS and viral hepatitis health care, prevention, education, and supportive services programs funded by state and federal governments. For more information, visit www.NASTAD.org [i] Reference:  Centers for Disease Control and Prevention.  (HIV/AIDS data through December 2008 provided for the Ryan White HIV/AIDS Treatment Extension Act of 2009, for fiscal year 2010. HIV Surveillance Supplemental Report 2012; 17(No. 1))   [ii]  http://www.iom.edu/Reports/2012/Monitoring-HIV-Care-in-the-United-States.aspx
http://transitionrx.com/news/action,view/id,5/HIV/AIDS-patient-assistance-foundation-HarborPath-teams-up-with-TPS-for--the-design,-development,-and-ongoing-operation-of-a-innovative-medication-access-system-for-underserved-patients. Jason Riddle 1440